Brain infections reported with MS drug
Washington, April 23, 2011
More than 100 cases of a potentially fatal brain infection have been reported among patients who took Biogen Idec's multiple sclerosis drug Tysabri, US health officials said.
The Food and Drug Administration also said it was updating prescribing instructions for Tysabri to warn doctors about how the risk for the brain infection, progressive multiform leukoencephalopathy (PML), changes over time.
Biogen, which makes Tysabri with Irish drugmaker Elan Corp, temporarily withdrew the medicine in 2005 after the first PML cases. The drug returned to the market with stricter warnings in 2006, although concerns about PML have crimped sales. – Reuters
More Health & Environment Stories
- ADSW to focus on energy-water nexus
- Bahrain moves to combat marine pollution
- Saudi hospital implements patient safety project
- Vasilica Aesthetics opens Dubai office
- NCDs ‘to cost GCC $36bn in 2013’
- Arabtec inks $1.2bn UAE hospital contract
- Infectious disease control ‘urgent need for GCC’
- New HIV cases fall as Bahrain's efforts pay off
- Conference to discuss emergency medicine
- UAE reports 3 more MERS cases